• 25-FEB-2015

  • SOURCE: Mundipharma International Limited

For European medical media only. Mundipharma launches Remsima®▼ (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma Logo
Mundipharma International Limited's network of independent associated companies are launching Remsima (infliximab) In February in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates.

Remsima is the first authorised biosimilar monoclonal antibody and is licenced by the European Medicines Agency (EMA) for the treatment of chronic, debilitating and often painful inflammatory autoimmune conditions that affect over seven million people across Europe.